BioMarin (BMRN) Form 144 lists proposed brokered share sales

BioMarin Pharmaceutical Inc. notice of proposed sale of common stock on a Form 144 through a broker-dealer.

Rhea-AI Filing Summary

BioMarin Pharmaceutical Inc. notice of proposed sale of common stock on a Form 144 through a broker-dealer. The filing lists Fidelity Brokerage Services LLC and references proposed transactions tied to restricted stock vesting on 09/30/2025 (5928 shares) and an ESPP purchase on 10/31/2025 (398 shares). The form records the broker and an entry date of 02/26/2026.

Insights

Securities Compliance Officer

Form 144 registers proposed brokered sales tied to employee share events.

The filing lists Fidelity Brokerage Services LLC as the broker and shows proposed dispositions connected to 09/30/2025 restricted stock vesting (5928 shares) and an 10/31/2025 ESPP purchase (398 shares). These entries reflect planned transfers through an intermediary rather than company-led offerings.

Reportable sales under Rule 144 require the broker notice; timing and execution depend on the broker and any applicable holding-period or volume limitations. Subsequent filings will show whether these proposed sales were executed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does BMRN's Form 144 filed with Fidelity indicate?

It indicates a proposed sale of BioMarin common stock through a broker-dealer. The form shows broker details and ties proposed dispositions to restricted stock vesting and an ESPP purchase on specific dates, listing 5928 shares and 398 shares respectively.

Who is the broker named on the Form 144 for BMRN?

The broker is Fidelity Brokerage Services LLC. The filing lists Fidelity's address and identifies it as the broker-dealer handling the proposed transactions noted on the Form 144.

What quantities and events are listed on the Form 144 for BMRN?

The form lists 5928 shares tied to restricted stock vesting on 09/30/2025 and 398 shares tied to an ESPP purchase on 10/31/2025. Each number appears next to its event date in the filing excerpt.

Does the Form 144 confirm these sales were completed?

No, the Form 144 reports proposed brokered sales under Rule 144 rather than completed transactions. Execution and settlement are not confirmed here; follow-up filings would disclose whether the proposed sales were executed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 01:59 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002038768
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BIOMARIN PHARMACEUTICAL INC
SEC File Number	000-26727
Address of Issuer	105 DIGITAL DRIVE NOVATO CALIFORNIA 94949
Phone	4155066700
Name of Person for Whose Account the Securities are To Be Sold	Friberg Gregory R
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	6326	381937.07	192323359	02/26/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/30/2025	Restricted Stock Vesting	Issuer			5928	09/30/2025	Compensation
Common	10/31/2025	ESPP Purchase	Issuer			398	10/31/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Audrey McMillen, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Gregory Friberg
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)